231 related articles for article (PubMed ID: 25655609)
1. Prognosis and therapy of chronic lymphocytic leukemia and small lymphocytic lymphoma.
Sun C; Wiestner A
Cancer Treat Res; 2015; 165():147-75. PubMed ID: 25655609
[TBL] [Abstract][Full Text] [Related]
2. Multicenter study of ZAP-70 expression in patients with B-cell chronic lymphocytic leukemia using an optimized flow cytometry method.
Gachard N; Salviat A; Boutet C; Arnoulet C; Durrieu F; Lenormand B; Leprêtre S; Olschwang S; Jardin F; Lafage-Pochitaloff M; Penther D; Sainty D; Reminieras L; Feuillard J; Béné MC;
Haematologica; 2008 Feb; 93(2):215-23. PubMed ID: 18223290
[TBL] [Abstract][Full Text] [Related]
3. Additional genetic high-risk features such as 11q deletion, 17p deletion, and V3-21 usage characterize discordance of ZAP-70 and VH mutation status in chronic lymphocytic leukemia.
Kröber A; Bloehdorn J; Hafner S; Bühler A; Seiler T; Kienle D; Winkler D; Bangerter M; Schlenk RF; Benner A; Lichter P; Döhner H; Stilgenbauer S
J Clin Oncol; 2006 Feb; 24(6):969-75. PubMed ID: 16418492
[TBL] [Abstract][Full Text] [Related]
4. ZAP-70 methylation and expression status in chronic lymphocytic leukemia.
Stilgenbauer S
Haematologica; 2005 Aug; 90(8):1012. PubMed ID: 16079094
[No Abstract] [Full Text] [Related]
5. ZAP-70 expression is a prognostic factor in chronic lymphocytic leukemia.
Dürig J; Nückel H; Cremer M; Führer A; Halfmeyer K; Fandrey J; Möröy T; Klein-Hitpass L; Dührsen U
Leukemia; 2003 Dec; 17(12):2426-34. PubMed ID: 14523469
[TBL] [Abstract][Full Text] [Related]
6. Clinical implications of ZAP-70 expressionin chronic lymphocytic leukemia.
Bosch F; Muntañola A; Giné E; Carrió A; Villamor N; Moreno C; Crespo M; Montserrat E
Cytometry B Clin Cytom; 2006 Jul; 70(4):214-7. PubMed ID: 16906580
[TBL] [Abstract][Full Text] [Related]
7. Modern and conventional prognostic markers of chronic lymphocytic leukaemia in the everyday haematological practice.
Doubek M; Mayer J; Obrtlíková P; Smolej L; Cmunt E; Schwarz J; Brejcha M; Kozmon P; Pospíšilová S; Brychtová Y; Pospíšil Z; Trněný M
Eur J Haematol; 2011 Aug; 87(2):130-7. PubMed ID: 21535162
[TBL] [Abstract][Full Text] [Related]
8. In vitro activity of 20 agents in different prognostic subgroups of chronic lymphocytic leukemia--rolipram and prednisolone active in cells from patients with poor prognosis.
Lindhagen E; Norberg M; Kanduri M; Tobin G; Säisänen L; Aberg M; Gustafsson MG; Sundström C; Rosenquist R; Aleskog A
Eur J Haematol; 2009 Jul; 83(1):22-34. PubMed ID: 19245531
[TBL] [Abstract][Full Text] [Related]
9. Updates in CLL: prognostic markers and their implication for treatment strategies.
Clin Adv Hematol Oncol; 2007 Apr; 5(4 Suppl 7):4-14; quiz 15-6. PubMed ID: 17637593
[No Abstract] [Full Text] [Related]
10. Prognostic markers in chronic lymphocytic leukemia: a comprehensive review.
Van Bockstaele F; Verhasselt B; Philippé J
Blood Rev; 2009 Jan; 23(1):25-47. PubMed ID: 18599169
[TBL] [Abstract][Full Text] [Related]
11. New prognostic markers in chronic lymphocytic leukemia.
Moreno C; Montserrat E
Blood Rev; 2008 Jul; 22(4):211-9. PubMed ID: 18448218
[TBL] [Abstract][Full Text] [Related]
12. Chronic lymphocytic leukemia: current and emerging treatment approaches.
Kay NE; Rai KR; O'Brien S
Clin Adv Hematol Oncol; 2006 Nov; 4(11 Suppl 22):1-10; quiz 11-2. PubMed ID: 17143256
[TBL] [Abstract][Full Text] [Related]
13. The addition of rituximab to fludarabine improves clinical outcome in untreated patients with ZAP-70-negative chronic lymphocytic leukemia.
Del Poeta G; Del Principe MI; Consalvo MA; Maurillo L; Buccisano F; Venditti A; Mazzone C; Bruno A; Gianní L; Capelli G; Lo Coco F; Cantonetti M; Gattei V; Amadori S
Cancer; 2005 Dec; 104(12):2743-52. PubMed ID: 16284990
[TBL] [Abstract][Full Text] [Related]
14. Combined analysis of ZAP-70 and CD38 expression as a predictor of disease progression in B-cell chronic lymphocytic leukemia.
Schroers R; Griesinger F; Trümper L; Haase D; Kulle B; Klein-Hitpass L; Sellmann L; Dührsen U; Dürig J
Leukemia; 2005 May; 19(5):750-8. PubMed ID: 15759031
[TBL] [Abstract][Full Text] [Related]
15. Chronic lymphocytic leukemia (CLL): first-line treatment.
Hallek M;
Hematology Am Soc Hematol Educ Program; 2005; ():285-91. PubMed ID: 16304393
[TBL] [Abstract][Full Text] [Related]
16. Low CD49d expression and long telomere identify a chronic lymphocytic leukemia subset with highly favourable outcome.
Rossi D; Bodoni CL; Zucchetto A; Rasi S; De Paoli L; Fangazio M; Rossi FM; Ladetto M; Gattei V; Gaidano G
Am J Hematol; 2010 Aug; 85(8):619-22. PubMed ID: 20578200
[No Abstract] [Full Text] [Related]
17. Variability of ZAP 70 expression in a patient with CLL.
Chaar BT; Grosso L; Petruska PJ
Am J Hematol; 2006 Aug; 81(8):645. PubMed ID: 16823829
[No Abstract] [Full Text] [Related]
18. [ZAP-70--a marker in chronic B-cell lymphocytic leukemia].
Bogdanov AN; Krivolanov IuA; Zaĭtsev KA; Kamilova TA
Vopr Onkol; 2008; 54(1):7-18. PubMed ID: 18416051
[No Abstract] [Full Text] [Related]
19. Recent advances in chronic lymphocytic leukemia.
Vyas N; Hassan A
Indian J Cancer; 2012; 49(1):137-43. PubMed ID: 22842181
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of ZAP-70 expression in chronic lymphocytic leukemia as assessed by quantitative polymerase chain reaction and flow cytometry.
Adams RL; Cheung C; Banh R; Saal R; Cross D; Gill D; Self M; Klein K; Mollee P
Cytometry B Clin Cytom; 2014 Mar; 86(2):80-90. PubMed ID: 24127306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
